{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:00:05Z","timestamp":1790269205195,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024075","name":"Region of Southern Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004196","name":"Odense University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.iotech.2026.101610","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:14:24Z","timestamp":1787595264000},"page":"101610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-4335","authenticated-orcid":false,"given":"S.K.","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7343-9398","authenticated-orcid":false,"given":"S.","family":"Madley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-6572","authenticated-orcid":false,"given":"J.","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"L.","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"C.H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iotech.2026.101610_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/medsci9040063","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"10","key":"10.1016\/j.iotech.2026.101610_bib2","article-title":"Trends in melanoma incidence, prevalence, stage at diagnosis, and survival: an analysis of the United States Cancer Statistics (USCS) database","volume":"16","author":"Okobi","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.iotech.2026.101610_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.iotech.2026.101610_bib4","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.iotech.2026.101610_bib5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.iotech.2026.101610_bib6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101610_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325\/KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.iotech.2026.101610_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.iotech.2026.101610_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor-induced diarrhoea and colitis: incidence and management. a systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.iotech.2026.101610_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.iotech.2026.101610_bib11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","article-title":"Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.iotech.2026.101610_bib12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.iotech.2026.101610_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.iotech.2026.101610_bib14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2026.101610_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"36","key":"10.1016\/j.iotech.2026.101610_bib16","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.iotech.2026.101610_bib17","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.iotech.2026.101610_bib18","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101610_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40487-025-00349-z","article-title":"Clinical management and outcomes of immune-related adverse events during treatment with immune checkpoint inhibitor therapies in melanoma and renal cell carcinoma: a UK Real-World evidence study","volume":"13","author":"Olsson-Brown","year":"2025","journal-title":"Oncol Ther"},{"issue":"9","key":"10.1016\/j.iotech.2026.101610_bib20","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/apt.17201","article-title":"Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis","volume":"56","author":"Dahl","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.iotech.2026.101610_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.101943","article-title":"The Danish Metastatic Melanoma Database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients","volume":"73","author":"Ellebaek","year":"2021","journal-title":"Cancer Epidemiol"},{"issue":"9596","key":"10.1016\/j.iotech.2026.101610_bib22","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.iotech.2026.101610_bib23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101610_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.iotech.2026.101610_bib25","article-title":"Benchmark for evaluation of Danish clinical word embeddings","volume":"9","author":"Laursen","year":"2023","journal-title":"North Eur J Lang Technol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101610_bib26","article-title":"The Akaike information criterion: background, derivation, properties, application, interpretation, and refinements","volume":"11","author":"Cavanaugh","year":"2019","journal-title":"Wiley Interdisicip Rev Comput Stat"},{"issue":"1","key":"10.1016\/j.iotech.2026.101610_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.iotech.2026.101610_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.iotech.2026.101610_bib28","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.iotech.2026.101610_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.iotech.2026.101610_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/cancers15030691","article-title":"Immune-related adverse events of the gastrointestinal system","volume":"15","author":"Nicolaides","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.iotech.2026.101610_bib32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.iotech.2026.101610_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.iotech.2026.101610_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000585","article-title":"Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma","volume":"5","author":"Favara","year":"2020","journal-title":"ESMO Open"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:01:05Z","timestamp":1790265665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S2590018826000298"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101610","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101610"}}